Comparative Modeling to Inform Cervical Cancer Control Policies

比较模型为宫颈癌控制政策提供信息

• 批准号: 8969095
• 负责人: Ruanne Vanessa Barnabas
• 金额: $ 121.27万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-09 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8969095
• 关键词: Address; Australia; Cancer Burden; Cancer Control; Cancer Intervention and Surveillance Modeling Network; Cervical; Cervical Cancer Screening; Cervix Uteri; Clinical; Clinical Research; Clinical Trials; Collaborations; Communities; Complex; Consensus; Country; Cytology; Data; Decision Making; Development; Disease; Disease Outcome; Ethnic Origin; Guidelines; HIV; HIV Seropositivity; Health; Health Benefit; Health Policy; Human Papilloma Virus Vaccination; Human Papillomavirus; Incidence; Individual; Intervention; Kenya; Malignant neoplasm of cervix uteri; Modeling; Netherlands; Outcome; Patients; Policies; Policy Maker; Population; Prevention strategy; Process; Provider; Race; Research; Route; Series; South Africa; Subgroup; Technology; Time; Uganda; United States; Vaccinated; Vaccination; Vaccines; Variant; Virus; Woman; base; cancer health disparity; carcinogenesis; cervical cancer prevention; comparative; comparative effectiveness; cost; cost effective; cost effectiveness; disease natural history; frontier; high risk; improved; innovation; mathematical model; mortality; new technology; programs; public health relevance; screening; shared decision making; trend; uptake; vaccination strategy; vaccine evaluation

 DESCRIPTION (provided by applicant): Despite successful cervical cancer screening in the United States, over 12,000 women develop and 4,000 women die from cervical cancer each year. New technologies, including screening tests and vaccines against human papillomavirus (HPV), a sexually-transmitted virus known to cause cervical cancer, represent tremendous opportunities for innovative and efficient cervical cancer programs in the U.S. but also pose significant challenges for decision making, due to the complex and long natural history of disease and the different time points along the disease spectrum at which interventions are applied. Consequently, policy makers are uniquely reliant on mathematical modeling to provide evidence on the optimal cervical cancer control strategies. These models can be used to integrate the most up-to-date data, extrapolate current short- term findings into long-term outcomes, and evaluate what-if scenarios that would otherwise be impractical or infeasible to conduct in clinical studies. There has been a growing number of independent mathematical models that have been developed to address clinical and policy questions with respect to cervical cancer prevention and control but no formal efforts to compare assumptions and results across models. As part of the CISNET consortium, a group of established cervical cancer modelers from the U.S., Australia, and the Netherlands will engage in a formal collaboration of comparative modeling using a series of state-of-the-art mathematical models of HPV and cervical carcinogenesis. We will pursue analyses related to the historical impact of screening, the comparative effectiveness of current and anticipated HPV vaccination and screening strategies, and optimal routes for reducing cervical cancer disparities.